Kumari S
Triple Negative Breast Cancer (TNBC) is a highly heterogeneous and aggressive subtype of breast cancer. Tumor microenvironment has been identified as a major regulator of carcinogenesis and imparting drug resistance to the proliferating cancer cells. Microenvironment conditions has been identified to promote altered metabolism which is one of the major factors in contributing to drug resistance of TNBC. Thus, identification of specific metabolic inhibitor and use of combinational drug therapy may be proven as a mainstay of treatment for triple negative breast cancer. Oxidative stress caused by ROS a byproduct of metabolic processes is associated with tumorigenesis and metastasis of breast cancer. Generally high levels of ROS have been identified in TME which contributes in cancer progression and aggressiveness. Thus, early detection of ROS level may be clinically advantageous to prevent further progression and aggressiveness of TNBC.
